Impurity profile study of repaglinide
Three unknown impurities and a byproduct in repaglinide bulk drug at levels below 0.1% (ranging from 0.05 to 0.1%) were detected by a simple isocratic reversed-phase high performance liquid chromatography (HPLC) method. These impurities were isolated from crude sample of repaglinide using reversed-p...
Gespeichert in:
| Veröffentlicht in: | Journal of pharmaceutical and biomedical analysis 2003-07, Vol.32 (3), p.461-467 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 467 |
|---|---|
| container_issue | 3 |
| container_start_page | 461 |
| container_title | Journal of pharmaceutical and biomedical analysis |
| container_volume | 32 |
| creator | Krishna Reddy, K.V.S.R. Moses Babu, J. Mathad, Vijayavitthal T. Eswaraiah, S. Satyanarayana Reddy, M. Dubey, P.K. Vyas, K. |
| description | Three unknown impurities and a byproduct in repaglinide bulk drug at levels below 0.1% (ranging from 0.05 to 0.1%) were detected by a simple isocratic reversed-phase high performance liquid chromatography (HPLC) method. These impurities were isolated from crude sample of repaglinide using reversed-phase preparative high performance liquid chromatography. Based on the spectroscopic data (IR, NMR and MS) the structures of these impurities (I, II and IV) and byproduct (III) were characterised as 4-carboxymethyl-2-ethoxy-benzoic acid (I), 4-cyclohexylaminocarbamoylmethyl-2-ethoxy-benzoic acid (II), 1-cyclohexyl-3-[3-methyl-1-(2-piperidin-1-yl-phenyl)-butyl]-urea (IV) and 1,3-dicyclohexyl urea (III), respectively. Their synthesis and formation is discussed. |
| doi_str_mv | 10.1016/S0731-7085(03)00216-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71286113</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0731708503002164</els_id><sourcerecordid>71286113</sourcerecordid><originalsourceid>FETCH-LOGICAL-c391t-9768893d8d7e1934cd5e7ebb45e6c637d8eafe2e89a34ce0897ff422d8a84b493</originalsourceid><addsrcrecordid>eNqFkMtKAzEUhoMotlYfQemmoovRZHJfiRQvhYILFdyFTHJGItNOTWaEvr3TdlB3rs7ifP-5fAidEnxFMBHXz1hSkkms-AWmlxjnRGRsDw2JkjTLBXvbR8MfZICOUvrAGHOi2SEaEMYF5xwP0WS2WLUxNOvxKtZlqGCcmtavx3U5jrCy71VYBg_H6KC0VYKTvo7Q6_3dy_Qxmz89zKa388xRTZpMS6GUpl55CURT5jwHCUXBOAgnqPQKbAk5KG27JmClZVmyPPfKKlYwTUfofDe3O-azhdSYRUgOqsouoW6TkSRXghDagXwHulinFKE0qxgWNq4NwWbjx2z9mM3zBlOz9WNYlzvrF7TFAvxvqhfSAZMesMnZqox26UL6w2mqudgMutlx0On4ChBNcgGWDnyI4Brj6_DPKd_HIoDH</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71286113</pqid></control><display><type>article</type><title>Impurity profile study of repaglinide</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Krishna Reddy, K.V.S.R. ; Moses Babu, J. ; Mathad, Vijayavitthal T. ; Eswaraiah, S. ; Satyanarayana Reddy, M. ; Dubey, P.K. ; Vyas, K.</creator><creatorcontrib>Krishna Reddy, K.V.S.R. ; Moses Babu, J. ; Mathad, Vijayavitthal T. ; Eswaraiah, S. ; Satyanarayana Reddy, M. ; Dubey, P.K. ; Vyas, K.</creatorcontrib><description>Three unknown impurities and a byproduct in repaglinide bulk drug at levels below 0.1% (ranging from 0.05 to 0.1%) were detected by a simple isocratic reversed-phase high performance liquid chromatography (HPLC) method. These impurities were isolated from crude sample of repaglinide using reversed-phase preparative high performance liquid chromatography. Based on the spectroscopic data (IR, NMR and MS) the structures of these impurities (I, II and IV) and byproduct (III) were characterised as 4-carboxymethyl-2-ethoxy-benzoic acid (I), 4-cyclohexylaminocarbamoylmethyl-2-ethoxy-benzoic acid (II), 1-cyclohexyl-3-[3-methyl-1-(2-piperidin-1-yl-phenyl)-butyl]-urea (IV) and 1,3-dicyclohexyl urea (III), respectively. Their synthesis and formation is discussed.</description><identifier>ISSN: 0731-7085</identifier><identifier>EISSN: 1873-264X</identifier><identifier>DOI: 10.1016/S0731-7085(03)00216-4</identifier><identifier>PMID: 14565550</identifier><identifier>CODEN: JPBADA</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Analysis ; Biological and medical sciences ; Byproduct ; Carbamates - analysis ; Chromatography, High Pressure Liquid ; Drug Contamination ; General pharmacology ; Hypoglycemic Agents - analysis ; Identification and characterisation ; Impurities ; Magnetic Resonance Spectroscopy ; Mass Spectrometry ; Medical sciences ; Pharmacology. Drug treatments ; Piperidines - analysis ; Repaglinide ; Spectroscopy ; Spectroscopy, Fourier Transform Infrared</subject><ispartof>Journal of pharmaceutical and biomedical analysis, 2003-07, Vol.32 (3), p.461-467</ispartof><rights>2003 Elsevier Science B.V.</rights><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c391t-9768893d8d7e1934cd5e7ebb45e6c637d8eafe2e89a34ce0897ff422d8a84b493</citedby><cites>FETCH-LOGICAL-c391t-9768893d8d7e1934cd5e7ebb45e6c637d8eafe2e89a34ce0897ff422d8a84b493</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0731708503002164$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14939564$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14565550$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Krishna Reddy, K.V.S.R.</creatorcontrib><creatorcontrib>Moses Babu, J.</creatorcontrib><creatorcontrib>Mathad, Vijayavitthal T.</creatorcontrib><creatorcontrib>Eswaraiah, S.</creatorcontrib><creatorcontrib>Satyanarayana Reddy, M.</creatorcontrib><creatorcontrib>Dubey, P.K.</creatorcontrib><creatorcontrib>Vyas, K.</creatorcontrib><title>Impurity profile study of repaglinide</title><title>Journal of pharmaceutical and biomedical analysis</title><addtitle>J Pharm Biomed Anal</addtitle><description>Three unknown impurities and a byproduct in repaglinide bulk drug at levels below 0.1% (ranging from 0.05 to 0.1%) were detected by a simple isocratic reversed-phase high performance liquid chromatography (HPLC) method. These impurities were isolated from crude sample of repaglinide using reversed-phase preparative high performance liquid chromatography. Based on the spectroscopic data (IR, NMR and MS) the structures of these impurities (I, II and IV) and byproduct (III) were characterised as 4-carboxymethyl-2-ethoxy-benzoic acid (I), 4-cyclohexylaminocarbamoylmethyl-2-ethoxy-benzoic acid (II), 1-cyclohexyl-3-[3-methyl-1-(2-piperidin-1-yl-phenyl)-butyl]-urea (IV) and 1,3-dicyclohexyl urea (III), respectively. Their synthesis and formation is discussed.</description><subject>Analysis</subject><subject>Biological and medical sciences</subject><subject>Byproduct</subject><subject>Carbamates - analysis</subject><subject>Chromatography, High Pressure Liquid</subject><subject>Drug Contamination</subject><subject>General pharmacology</subject><subject>Hypoglycemic Agents - analysis</subject><subject>Identification and characterisation</subject><subject>Impurities</subject><subject>Magnetic Resonance Spectroscopy</subject><subject>Mass Spectrometry</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Piperidines - analysis</subject><subject>Repaglinide</subject><subject>Spectroscopy</subject><subject>Spectroscopy, Fourier Transform Infrared</subject><issn>0731-7085</issn><issn>1873-264X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMtKAzEUhoMotlYfQemmoovRZHJfiRQvhYILFdyFTHJGItNOTWaEvr3TdlB3rs7ifP-5fAidEnxFMBHXz1hSkkms-AWmlxjnRGRsDw2JkjTLBXvbR8MfZICOUvrAGHOi2SEaEMYF5xwP0WS2WLUxNOvxKtZlqGCcmtavx3U5jrCy71VYBg_H6KC0VYKTvo7Q6_3dy_Qxmz89zKa388xRTZpMS6GUpl55CURT5jwHCUXBOAgnqPQKbAk5KG27JmClZVmyPPfKKlYwTUfofDe3O-azhdSYRUgOqsouoW6TkSRXghDagXwHulinFKE0qxgWNq4NwWbjx2z9mM3zBlOz9WNYlzvrF7TFAvxvqhfSAZMesMnZqox26UL6w2mqudgMutlx0On4ChBNcgGWDnyI4Brj6_DPKd_HIoDH</recordid><startdate>20030714</startdate><enddate>20030714</enddate><creator>Krishna Reddy, K.V.S.R.</creator><creator>Moses Babu, J.</creator><creator>Mathad, Vijayavitthal T.</creator><creator>Eswaraiah, S.</creator><creator>Satyanarayana Reddy, M.</creator><creator>Dubey, P.K.</creator><creator>Vyas, K.</creator><general>Elsevier B.V</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20030714</creationdate><title>Impurity profile study of repaglinide</title><author>Krishna Reddy, K.V.S.R. ; Moses Babu, J. ; Mathad, Vijayavitthal T. ; Eswaraiah, S. ; Satyanarayana Reddy, M. ; Dubey, P.K. ; Vyas, K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c391t-9768893d8d7e1934cd5e7ebb45e6c637d8eafe2e89a34ce0897ff422d8a84b493</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Analysis</topic><topic>Biological and medical sciences</topic><topic>Byproduct</topic><topic>Carbamates - analysis</topic><topic>Chromatography, High Pressure Liquid</topic><topic>Drug Contamination</topic><topic>General pharmacology</topic><topic>Hypoglycemic Agents - analysis</topic><topic>Identification and characterisation</topic><topic>Impurities</topic><topic>Magnetic Resonance Spectroscopy</topic><topic>Mass Spectrometry</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Piperidines - analysis</topic><topic>Repaglinide</topic><topic>Spectroscopy</topic><topic>Spectroscopy, Fourier Transform Infrared</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Krishna Reddy, K.V.S.R.</creatorcontrib><creatorcontrib>Moses Babu, J.</creatorcontrib><creatorcontrib>Mathad, Vijayavitthal T.</creatorcontrib><creatorcontrib>Eswaraiah, S.</creatorcontrib><creatorcontrib>Satyanarayana Reddy, M.</creatorcontrib><creatorcontrib>Dubey, P.K.</creatorcontrib><creatorcontrib>Vyas, K.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of pharmaceutical and biomedical analysis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Krishna Reddy, K.V.S.R.</au><au>Moses Babu, J.</au><au>Mathad, Vijayavitthal T.</au><au>Eswaraiah, S.</au><au>Satyanarayana Reddy, M.</au><au>Dubey, P.K.</au><au>Vyas, K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impurity profile study of repaglinide</atitle><jtitle>Journal of pharmaceutical and biomedical analysis</jtitle><addtitle>J Pharm Biomed Anal</addtitle><date>2003-07-14</date><risdate>2003</risdate><volume>32</volume><issue>3</issue><spage>461</spage><epage>467</epage><pages>461-467</pages><issn>0731-7085</issn><eissn>1873-264X</eissn><coden>JPBADA</coden><abstract>Three unknown impurities and a byproduct in repaglinide bulk drug at levels below 0.1% (ranging from 0.05 to 0.1%) were detected by a simple isocratic reversed-phase high performance liquid chromatography (HPLC) method. These impurities were isolated from crude sample of repaglinide using reversed-phase preparative high performance liquid chromatography. Based on the spectroscopic data (IR, NMR and MS) the structures of these impurities (I, II and IV) and byproduct (III) were characterised as 4-carboxymethyl-2-ethoxy-benzoic acid (I), 4-cyclohexylaminocarbamoylmethyl-2-ethoxy-benzoic acid (II), 1-cyclohexyl-3-[3-methyl-1-(2-piperidin-1-yl-phenyl)-butyl]-urea (IV) and 1,3-dicyclohexyl urea (III), respectively. Their synthesis and formation is discussed.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>14565550</pmid><doi>10.1016/S0731-7085(03)00216-4</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0731-7085 |
| ispartof | Journal of pharmaceutical and biomedical analysis, 2003-07, Vol.32 (3), p.461-467 |
| issn | 0731-7085 1873-264X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71286113 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Analysis Biological and medical sciences Byproduct Carbamates - analysis Chromatography, High Pressure Liquid Drug Contamination General pharmacology Hypoglycemic Agents - analysis Identification and characterisation Impurities Magnetic Resonance Spectroscopy Mass Spectrometry Medical sciences Pharmacology. Drug treatments Piperidines - analysis Repaglinide Spectroscopy Spectroscopy, Fourier Transform Infrared |
| title | Impurity profile study of repaglinide |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T09%3A14%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impurity%20profile%20study%20of%20repaglinide&rft.jtitle=Journal%20of%20pharmaceutical%20and%20biomedical%20analysis&rft.au=Krishna%20Reddy,%20K.V.S.R.&rft.date=2003-07-14&rft.volume=32&rft.issue=3&rft.spage=461&rft.epage=467&rft.pages=461-467&rft.issn=0731-7085&rft.eissn=1873-264X&rft.coden=JPBADA&rft_id=info:doi/10.1016/S0731-7085(03)00216-4&rft_dat=%3Cproquest_cross%3E71286113%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71286113&rft_id=info:pmid/14565550&rft_els_id=S0731708503002164&rfr_iscdi=true |